163 related articles for article (PubMed ID: 26819111)
21. [Protein S100 beta and Melanoma Inhibitory Activity (MIA): a prospective study of their clinical value for the early detection of metastasis in malignant melanoma].
Loppin M; Quillien V; Adamski H; Ollivier I; Garlantézec R; Chevrant-Breton J
Ann Dermatol Venereol; 2007; 134(6-7):535-40. PubMed ID: 17657179
[TBL] [Abstract][Full Text] [Related]
22. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma.
Hauschild A; Engel G; Brenner W; Gläser R; Mönig H; Henze E; Christophers E
Oncology; 1999; 56(4):338-44. PubMed ID: 10343200
[TBL] [Abstract][Full Text] [Related]
23. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
24. Serum S100B Levels in Melanoma.
Frauchiger AL; Dummer R; Mangana J
Methods Mol Biol; 2019; 1929():691-700. PubMed ID: 30710305
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics.
Mruck S; Baum RP; Rinne D; Hör G
Anticancer Res; 1999; 19(4A):2685-90. PubMed ID: 10470220
[TBL] [Abstract][Full Text] [Related]
26. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis.
Mocellin S; Zavagno G; Nitti D
Int J Cancer; 2008 Nov; 123(10):2370-6. PubMed ID: 18752249
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
[TBL] [Abstract][Full Text] [Related]
28. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
Egberts F; Hitschler WN; Weichenthal M; Hauschild A
Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
[TBL] [Abstract][Full Text] [Related]
29. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta.
Juergensen A; Holzapfel U; Hein R; Stolz W; Buettner R; Bosserhoff A
Tumour Biol; 2001; 22(1):54-8. PubMed ID: 11054027
[TBL] [Abstract][Full Text] [Related]
30. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.
Felix J; Cassinat B; Porcher R; Schlageter MH; Maubec E; Pages C; Baroudjian B; Homyrda L; Boukouaci W; Tamouza R; Bagot M; Caignard A; Toubert A; Lebbé C; Moins-Teisserenc H
Int Immunopharmacol; 2016 Nov; 40():466-473. PubMed ID: 27728898
[TBL] [Abstract][Full Text] [Related]
31. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients.
Egberts F; Momkvist A; Egberts JH; Kaehler KC; Hauschild A
Anticancer Res; 2010 May; 30(5):1799-805. PubMed ID: 20592382
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker.
Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
Melanoma Res; 2003 Dec; 13(6):587-93. PubMed ID: 14646622
[TBL] [Abstract][Full Text] [Related]
33. Monthly changes in serum levels of S100B protein as a predictor of metastasis development in high-risk melanoma patients.
Ertekin SS; Podlipnik S; Ribero S; Molina R; Rios J; Carrera C; Malvehy J; Puig S
J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1482-1488. PubMed ID: 31967695
[TBL] [Abstract][Full Text] [Related]
34. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma.
Jury CS; McAllister EJ; MacKie RM
Br J Dermatol; 2000 Aug; 143(2):269-74. PubMed ID: 10951132
[TBL] [Abstract][Full Text] [Related]
35. [Serum levels of S-100b protein after four years follow-up of patients with melanoma].
Zissimopoulos A; Karpouzis A; Karaitianos I; Baziotis N; Tselios I; Koutis C
Hell J Nucl Med; 2006; 9(3):204-7. PubMed ID: 17160167
[TBL] [Abstract][Full Text] [Related]
36. Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells.
Schiltz PM; Dillman RO; Korse CM; Cubellis JM; Lee GJ; De Gast GC
Cancer Biother Radiopharm; 2008 Apr; 23(2):214-21. PubMed ID: 18454690
[TBL] [Abstract][Full Text] [Related]
37. Serum anti-BPAG1 autoantibody level is not a useful biomarker for cutaneous melanoma.
Gambichler T; Scheitz R; Höxtermann S
Melanoma Res; 2016 Feb; 26(1):88-9. PubMed ID: 26301970
[No Abstract] [Full Text] [Related]
38. Serum S100B levels correlate with clinical benefit in a metastatic melanoma patient treated by CTLA-4 blockade: a case report.
Loquai C; Müller-Brenne T; Schadmand-Fischer S; Grabbe S
Onkologie; 2013; 36(10):578-81. PubMed ID: 24107912
[TBL] [Abstract][Full Text] [Related]
39. Increased level of circulating U2 small nuclear RNA fragments indicates metastasis in melanoma patients.
Kuhlmann JD; Wimberger P; Wilsch K; Fluck M; Suter L; Brunner G
Clin Chem Lab Med; 2015 Mar; 53(4):605-11. PubMed ID: 25741740
[TBL] [Abstract][Full Text] [Related]
40. Serum markers in skin melanoma--preliminary study.
Dumitraşcu G; Constantin C; Manda G; Hristescu S; Mărgaritescu I; Chiriţă D; Neagu M
Roum Arch Microbiol Immunol; 2009; 68(3):125-35. PubMed ID: 20361532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]